Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study - Takeaways - MDSpire

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • By

  • Zhong Wang

  • Yimin Zhang

  • Feng Yao

  • Jinxin Li

  • Chenyuan Li

  • Shichong Liao

  • June 18, 2026

  • 0 min

Share

  • 1

    This study compared T-DM1 and trastuzumab plus pertuzumab in HER2-positive breast cancer patients with residual disease after neoadjuvant therapy.

  • 2

    T-DM1 showed a 38% reduction in recurrence risk compared to dual-target therapy, although the difference was not statistically significant.

  • 3

    Exploratory analyses indicated improved disease-free survival with T-DM1 in patients with initially unresectable disease or poor pathological response.

  • 4

    Grade ≥3 thrombocytopenia was significantly more frequent with T-DM1, highlighting a clinically important safety trade-off.

  • 5

    The findings suggest T-DM1 may benefit specific non-pCR patients, influencing treatment decisions in adjuvant therapy for HER2-positive breast cancer.

Original Source(s)

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

  • by Zhong Wang, Yimin Zhang, Feng Yao, Jinxin Li, Chenyuan Li, Shichong Liao

  • June 18, 2026

Related Content

Research advances and application prospects of CAR-T therapy in the treatment of age-related diseases

Homologous recombination pathway alterations in basal-like breast cancer

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support